Status:

COMPLETED

Phase III Clinical Study of Pegylated Somatropin (PEG Somatropin) to Treat Growth Hormone Deficiency Children

Lead Sponsor:

Changchun GeneScience Pharmaceutical Co., Ltd.

Collaborating Sponsors:

Tongji Hospital

First Affiliated Hospital, Sun Yat-Sen University

Conditions:

Growth Hormone Deficiency

Eligibility:

All Genders

8-15 years

Phase:

PHASE3

Brief Summary

This was a multicenter, randomized, open-label, parallel controlled phase III study, compared pegylated somatropin with Jintropin AQ (somatropin liquid injection, daily administration formulation). A...

Eligibility Criteria

Inclusion

  • 1\. Subjects have a height less than two standard deviations (SD) below the median height for individuals of he same age or height,the growth velocity (CV≤4.0 cm/yr),GH peak concentration \<7.0ng/ml in two difference provocative tests, Bone age (BA) ≤9 years in girls and ≤10 years in boys, at least 2 year less than his/her chronological age (CA)
  • be in preadolescence (Tanner stage 1) and have a CA \> 3 years
  • have a height value recorded 3 months before the start of GH treatment to calculate pre-treatment GV.
  • receive no prior GH treatment.
  • sign informed consent

Exclusion

  • 1\. patients positive for hepatitis B e-antibody (HBeAb), hepatitis B surface antigen (HBsAg) or hepatitis B e antigen (HBeAg)
  • Known hypersensitivity to Somatropin or any other components of the study product.
  • 3\. severe cardiopulmonary or hematological diseases, a current or past history of malignant tumors, immunodeficiency diseases, or mental diseases
  • 4\. with other growth disorders, such as Turner syndrome, constitutional delay of growth and puberty, and Laron syndrome
  • 5\. Subjects took part in other clinical trial study during 3 months.
  • 6\. Other conditions which in the opinion of the investigator preclude enrollment into the study.

Key Trial Info

Start Date :

March 1 2007

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

March 1 2008

Estimated Enrollment :

343 Patients enrolled

Trial Details

Trial ID

NCT01495468

Start Date

March 1 2007

End Date

March 1 2008

Last Update

July 31 2017

Active Locations (6)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 2 (6 locations)

1

Beijing, China

2

Changchun, China

3

Guangzhou, China

4

Hangzhou, China